Supplementary materials Methods Calculation of costs and HCRU A cost of €24.13, which included official tariffs and surcharges
![Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France - Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France -](https://onlinelibrary.wiley.com/cms/asset/31beac85-24ac-4c9c-858a-0fbd2a83d805/pds.v27.11.cover.jpg)
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France -
Medico-economic comparison of two anticoagulant treatment strategies: Vitamin K antagonists vs. direct oral anticoagulants in older adults in nursing homes in France. The “MIKADO” study | PLOS ONE
![Covid-19 : L'Assurance Maladie étend le téléservice declare.ameli.fr aux personnes à risque élevé - Viva Magazine Covid-19 : L'Assurance Maladie étend le téléservice declare.ameli.fr aux personnes à risque élevé - Viva Magazine](https://www.vivamagazine.fr/wp-content/uploads/2020/03/rea_285170_002.jpg)